Personalized CAR-T Immunotherapy Platform
Improved sensitivity for single gene mutation detection
IIn the era of the Cancer MoonShot 2020 Program — the nation’s most comprehensive cancer collaborative initiative to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients — DiaCarta and ProMab have joined hands to offer the next-generation Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy platform.
1500 existing hybridomas and antibody engineering
Custom lentiviral CAR construction (GMP)
High-throughput multiplex cytotoxicity assays
In vivo efficacy and toxicity validation
CAR-T cell manufacturing (GMP)
Biomarker discovery
Genomic profiling
Next-Generation Sequencing
CAR-T infusion treatment
Personalized CAR-T Immunotherapy Platform Service Overview
Genomic Profiling - Biomarker discovery and CAR-T profiling
- Gene mutation analysis by XNA technology
- Gene expression by QuantiMarker™ assays
- OptiSeq™ next-generation sequencing
- GLP and CLIA lab settings
Cytokines Assays - Bead-based multiplex protein tests run on Bio-Rad Bio-Plex®
- Standard assays for cytokine detection in activated CAR-T cells (e.g. IL-2, IL-6, IFN-ϒ)
- Customized assays for quantitating up to 50 cytokines
- GLP and CLIA lab settings
CAR-T Services - Focus on generating CAR for murine-based pre-clinical studies or use as a clinical tool
- Antibody discovery (hybridomas, mouse, rabbit and human library)
- Customized lentiviral CAR construction
- CAR-T cell manufacturing
- Real-time cytotoxicity assay (RTCA)
- Multiplex cytokine screening
- Mouse in vivo efficacy and toxicology
modeling - In vivo imaging by Xenogen/PerkinElmer IVIS system
- GMP manufacturing of CD3/CD28 beads (coming soon)
- GMP manufacturing of lentiviral CAR (coming soon)